RevBio
Private Company
Total funding raised: $5M
Overview
RevBio is pioneering the first synthetic bone adhesive with its TETRANITE platform, a bioinspired biomaterial that functions as both a fixation device and a scaffold for bone regeneration. The company's lead program is in a first-in-human clinical trial for cranial flap fixation, supported by a $2.4 million NIH grant, and it has a pipeline targeting significant opportunities in dental stabilization, dental bone grafting, and orthopedics. As a private, pre-revenue company, RevBio's technology addresses a long-standing unmet need in surgery, potentially replacing metal hardware with a resorbable adhesive that improves healing outcomes and reduces procedure complexity across multiple surgical specialties.
Technology Platform
TETRANITE is a synthetic, mineral-organic regenerative adhesive biomaterial platform, bioinspired by the sandcastle worm. It is a two-component system that hardens in wet fields, bonds to bone and metal, provides immediate mechanical strength (~3 MPa), and is osteoconductive and fully resorbable, being replaced by native bone over time.
Funding History
1Opportunities
Risk Factors
Competitive Landscape
The direct competitive landscape for a synthetic, resorbable bone adhesive is currently sparse, giving RevBio a potential first-mover advantage. However, it competes indirectly with the entrenched standard of care: metal fixation hardware (plates, screws) in fixation and various bone graft substitutes (allografts, synthetics, BMPs) in fusion. Larger players like Stryker, DePuy Synthes, and Zimmer Biomet have vast resources and could develop or acquire competing technologies.